

specific quality criteria developed by the authors. **RESULTS:** We found 45 comparative studies in 43 publications. Asthma (14 studies) and psychiatric illness (12 studies) were most commonly investigated. In 33 studies, interventions were educational, 20 had multiple components and 23 did not appear to be linked to proven reasons for non-adherence. No studies assessed management of unintentional non-adherence. No study met all quality criteria. Study quality has not improved with time, as some better studies are over ten years old. Many studies used inadequate or unidentifiable adherence measures. Critically, many were too small or not randomised. All studies assumed that patients were prescribed appropriate therapy for their condition, and no assessment of treatment quality was made by any study. Reporting of adherence and outcome results was often unclear. Cost data were poorer quality than outcome data, using average or estimated costs and omitting some cost elements. Nine studies carried out incremental economic analysis. **CONCLUSIONS:** We were not able to make definitive conclusions about the cost-effectiveness of medication adherence enhancing interventions due to the heterogeneity of the studies found and incomplete reporting of results. Important policy decisions need to be made about non-adherence, however, they are currently being made in a vacuum of adequate information. Medication adherence-enhancing interventions must be based on reasons for non-adherence and be evaluated using accepted clinical and economic quality criteria.

**PHP2****THE MEDINET-PROJECT—A FEASIBILITY STUDY ON MEDICATION COMPLIANCE UNDER REAL LIFE CONDITIONS**

Sterz R<sup>1</sup>, Lebmeier M<sup>2</sup>, Simon U<sup>3</sup>

<sup>1</sup>Abbott GmbH & Co. KG, Ludwigshafen, Rhineland-Palati, Germany;

<sup>2</sup>Sheffield University, Sheffield, UK; <sup>3</sup>ES-Q-Lab, Lauf, Bavaria, Germany

**OBJECTIVES:** To study medication compliance patterns regarding dosing, timing and adherence under real life conditions. Using a new electronic blister pack system. **METHODS:** A total of 37 volunteers from three study centers were each furnished with an electronic blister holder (“monitor”) and three blister packs containing 14 placebo capsules each (trial duration: six-weeks). The monitor measured the disruption of conductive lines printed on aluminum carrier foil under each capsule and stored this information (date and time) for evaluation at the end of the study. Patients had to take out one capsule daily in the morning over the entire study period. Also patients received a CRF and a radio-controlled clock such that date and time of the event could be manually recorded by the patient as well. Data were considered accurate if the information stored in the monitor and the corresponding CRF entries were within a time window of  $\pm 15$  min. **RESULTS:** All recordings of the electronically stored information matched the data documented on the CRFs. This indicates the accurate documentation of the volunteers, as well as the correct functioning of the monitors. Evaluation of the data, however, showed a wide intra—as well as interindividual variation in the time patterns of the volunteers. Three clusters of time preference were detected—mornings, noon and late night. Further, periods of non-compliance (“drug holidays”) as well as lack of adherence (discontinuation of medication before the end of the study period of six-weeks) could be documented. **CONCLUSIONS:** The use of the new electronic blister system improves compliance measurement under real life conditions. Combining compliance information with other outcome parameters will help in better quantifying and optimizing the impact of patient compliance on clinical and economic outcomes under real life conditions.

**PHP3****IMPACT OF INCREASED COPAYMENTS ON THE SWITCHING AND DISCONTINUATION RATES FOR NON FORMULARY MEDICATIONS**

Nair KV<sup>1</sup>, Valuck RJ<sup>2</sup>

<sup>1</sup>University of Colorado Health Sciences Center, Denver, CO, USA;

<sup>2</sup>University of Colorado, Denver, CO, USA

**OBJECTIVE:** Chronic disease sufferers are particularly affected by prescription copayment increases as they are faced with decisions to switch to formulary alternatives or pay more to stay on their current medication. The objective of this study was to evaluate the impact of increased prescription copayments as a result of a change in formulary status on continuation rates of non formulary medications in multi-tiered pharmacy benefit plans. **METHODS:** Retrospective cohort study of chronic disease patients from a health plan in the Western U.S. Individuals were selected who were taking a medication that was being removed from the health plan’s formulary and thus experienced increases in their copayments for non formulary medications (n = 1244). Two time periods were studied: the “pre” period before and the “post” period after the increase in copayments. Adjusting for demographics, chronic co-morbidities, medication use, Medicare + Choice status and percentage increase in copayment for non formulary medications, Cox regressions were used to assess continuation rates for these medications. **RESULTS:** A clear relationship between increasing copayment differentials and continuation rates for non formulary medications in the post period could not be established. In general those who experienced higher copayment differentials (between 50–100%, 100–200% and greater than 200%) were more likely to continue their non formulary medication than those who experienced copayment increases of 25–50% and less than 25%. **CONCLUSIONS:** Individuals confronted with increased copayments often switched their medications to formulary alternatives. However, a clear relationship could not be established between increasing copayments and continuation behavior. Further research is needed to determine if these switching behaviors results in inappropriate medication behaviors such as complete discontinuation of drug therapy due to the increased costs.

**PHP4****IMPACT OF COST ON MEDICATION COMPLIANCE IN PATIENTS WITH DIFFERENT LEVELS OF PERCEIVED BENEFITS**

Fuldeore M<sup>1</sup>, Krueger KP<sup>2</sup>, Lee K<sup>1</sup>, Berger BA<sup>2</sup>, Bertram C<sup>1</sup>, Shannon D<sup>2</sup>, Ekelund R<sup>2</sup>

<sup>1</sup>Walgreens Health Initiatives, Deerfield, IL, USA; <sup>2</sup>Auburn University,

Auburn, AL, USA

**OBJECTIVES:** The economics theory of consumer behavior suggests that the impact of cost on product purchasing decisions depends on the perceived benefits associated with that product. However, this relationship has been neither demonstrated nor quantified for patients taking chronic medications. The objective of this study was thus to analyze the impact of cost on medication compliance (refills) among groups of individuals with different levels of perceived benefits. **METHODS:** Patients new to statin therapy were identified from the prescription database of a national retail chain. The perceived benefit of the statin medication was measured on a scale of one (low) to seven (high) by surveying randomly selected new patients. Compliance with the medication regimen during the first 12 months of statin therapy was measured in terms of the Medication Possession Ratio (MPR). Information on cost and (MPR) on randomly selected patients was obtained from the retail chain prescription data-